AIMOVIG DIN 02479605
Status: Approved
Holder: NOVARTIS PHARMACEUTICALS CANADA INC
Health Canada record
| Active ingredient(s) | ERENUMAB 70 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | N02CD01 ERENUMAB |
|---|
| Original market date | |
|---|
| Current status date | 01-Aug-2018 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Novartis Pharmaceuticals Canada Inc — licence 100273, currently licensed, last inspection rating C (2025-01-14).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ERENUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02479613 | AIMOVIG | NOVARTIS PHARMACEUTICALS CANADA INC | Solution | ERENUMAB 70 MG | Marketed |
| 02487292 | AIMOVIG | NOVARTIS PHARMACEUTICALS CANADA INC | Solution | ERENUMAB 140 MG | Approved |
| 02487306 | AIMOVIG | NOVARTIS PHARMACEUTICALS CANADA INC | Solution | ERENUMAB 140 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 21166 | 2018-08-01 | New Drug Submission (NDS) | |
Request a quote for AIMOVIG
How to read a Canadian DIN record